Company Filing History:
Years Active: 2015
Title: Frank Stowasswer: Innovator in Crystalline Forms
Introduction
Frank Stowasswer is an accomplished inventor based in Murg, Germany. He has made significant contributions to the field of pharmaceutical sciences, particularly through his innovative research and development efforts at Novartis AG. With one patent to his name, Stowasswer's work is characterized by a blend of creativity and scientific rigor.
Latest Patents
Frank Stowasswer holds a patent for the crystalline forms of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea and its salts. This patent describes novel anhydrous and hydrated crystalline forms of the compound, along with amorphous and anhydrous crystalline polymorphs of its monophosphoric acid salt and hydrochloride salt, including its dihydrate. The technology also encompasses methods for preparing these forms, various compositions containing them, and treatment methods utilizing these compounds.
Career Highlights
Throughout his career at Novartis AG, Frank Stowasswer has focused on the development of innovative pharmaceutical formulations. His patent showcases his ability to bridge chemistry and medicine, addressing critical needs in drug delivery and efficacy.
Collaborations
Frank has worked alongside notable colleagues, including Joerg Berghausen and Prasad Koteswara Kapa. Their collaborative efforts have contributed to advancements in their field, fostering innovation through shared knowledge and expertise.
Conclusion
Frank Stowasswer stands out as a dedicated inventor in the pharmaceutical industry. His innovative contributions, particularly in the realm of crystalline forms and their applications, reflect his commitment to advancing healthcare. As he continues to work at Novartis AG, his future endeavors are anticipated to yield further groundbreaking advancements in drug development.